The Relationship Between Relaxation or Wheat Germ Juice to the Immune Indices and Quality of Life (QoL) in Colorectal Cancer Patients on Adjuvant Chemotherapy

Colon Cancer Clinical Trial

Official title:

Examining the Relationship Between Relaxation Combined With Biofeedback or Wheat Germ Juice to the Immune Indices and Quality of Life Measures in Patients With Colorectal Cancer Who Receive Prophylactic Chemotherapy After Surgery

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT01991080
• Other study ID #: Biofeedback
• Status: Recruiting
• Phase: N/A
• First received: October 29, 2013
• Last updated: May 3, 2017
• Start date: December 2013
• Est. completion date: December 2018

Study information

• Verified date: May 2017
• Source: Rambam Health Care Campus
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The immune system plays an important role in the fight against cancer. According to certain studies, Levels of cytokines secreted by the immune cells were found as predictors of prognosis and survival among cancer patients, as well as disease recurrence. Previous studies, including meta-analyses, reported that chronic emotional stress or depression were associated with higher levels of pro-inflammatory cytokines. Practicing relaxation was found to decrease psychological symptoms among cancer patients, such as depression, anger, hostility and anxiety symptoms, as well as physical symptoms.

Wheatgrass juice is an extract squeezed from the mature sprouts of wheat seeds (Triticum aestivum). Currently, there are only a few laboratory and medical studies that examine the beneficial effects of wheatgrass consumption. Controlled clinical trials have found that wheatgrass juice may reduce chemotherapy-induced myelotoxicity, accompanied by fever and infection without harming the chemotherapy effectiveness among breast cancer patients6.

Aims

1. To examine the differences in immune measures (serum and micro-particles levels of the cytokines IL-6, IL-8, IL-10 and IL-12), and in physical and psychological well-being measures (anxiety, depression, pain, fatigue, nausea) at three time points and between two intervention methods (biofeedback-assisted relaxation and wheatgrass consumption) and between the intervention groups vs. a control group, among colorectal cancer patients.

2. To assess the mediating role of optimism, perceived control and well-being measures (anxiety, depression, pain, fatigue, nausea) among colorectal cancer patients in the relations between the interventions (biofeedback-assisted relaxation and wheatgrass consumption) and the immune measures (serum and micro-particles levels of cytokines IL-6, IL-8 IL-10 and IL-12 ), and the mediating role of well-being measures on the relations between optimism and perceived control with immune measures.

Methods Participants will include 120 colorectal cancer patients aged 18+, with Eastern performance status of ≤ 2 and disease stage II or III, who receive adjuvant chemotherapy of Capcitabine or FU-5 treatment, conjoined with Oxaliplatin, or Capcitabine alone following curative surgery at Rambam Health Care Campus. The estimated number of participants was calculated based on Green's equation (1991): 50+8X 7 A comparison between the two treatment groups, as well as a comparison between each treatment group and the control group (80 subjects) will allow inclusion of up to four background parameters in each of the regressions, according to Green's equation.

Description:

The immune system plays an important role in the fight against cancer. According to certain studies, Levels of cytokines secreted by the immune cells were found as predictors of prognosis and survival among cancer patients, as well as disease recurrence1. Pro-inflammatory cytokines, such as IL-6, IL-8 and IL-10 were found to be negative prognostic factors in different cancer types, including colorectal cancer, while IL-12 was found in several studies to be a positive prognostic factor. However, inconclusive results were found for the role of IL-12 and anti-inflammatory cytokines in cancer prognosis.

Previous studies, including meta-analyses, reported that chronic emotional stress or depression were associated with higher levels of pro-inflammatory cytokines2; furthermore, there is some, albeit inconclusive, evidence that they may predict lower survival rates3. Moreover, there is further evidence that personal resources such as optimism and control perceptions may have an effect on psychological and physical well-being (i.e., low level of psychological or physical symptoms in reaction to stressful events) and dysregulate immune functions such as levels of pro-inflammatory cytokines.

Practicing relaxation was found to decrease psychological symptoms among cancer patients, such as depression, anger, hostility and anxiety symptoms, as well as physical symptoms, including fatigue, insomnia and pain. In addition, relaxation may reduce nausea and vomiting following chemotherapy.

Several studies of cancer patients have reported positive associations between relaxation-based interventions and immune measures, such as an elevated rate of T-cell subpopulations as well as increased IL-4 production and decreased IL-10 production4. Similarly, biofeedback-assisted relaxation was associated with enhanced natural killer cell activity, lymphocyte responsiveness, and the number of peripheral blood lymphocytes5. However, results are not always conclusive, and the few studies investigating the relationship between relaxation training and immune measures have often included small and uncontrolled samples.

Wheatgrass juice is an extract squeezed from the mature sprouts of wheat seeds (Triticum aestivum). Currently, there are only a few laboratory and medical studies that examine the beneficial effects of wheatgrass consumption. These studies tend to report positive effects with minimal side effects among patients with arthritis, thalassemia and ulcerative colitis. Lab research has demonstrated that wheatgrass consumption caused a prolonged latent period of skin cancer in mice. Controlled clinical trials have found that wheatgrass juice may reduce chemotherapy-induced myelotoxicity, accompanied by fever and infection without harming the chemotherapy effectiveness among breast cancer patients6.

Aims

In light of the lack of studies examining the effects of wheatgrass consumption on immune and well-being measures, as well as limited data from few studies regarding the effects of biofeedback-assisted relaxation on immune parameters, the aims of the current study are as follow:

1. To examine the differences in immune measures (serum and micro-particles levels of the cytokines IL-6, IL-8, IL-10 and IL-12), and in physical and psychological well-being measures (anxiety, depression, pain, fatigue, nausea) at three time points and between two intervention methods (biofeedback-assisted relaxation and wheatgrass consumption) and between the intervention groups vs. a control group, among colorectal cancer patients.

2. To assess the mediating role of optimism, perceived control and well-being measures (anxiety, depression, pain, fatigue, nausea) among colorectal cancer patients in the relations between the interventions (biofeedback-assisted relaxation and wheatgrass consumption) and the immune measures (serum and micro-particles levels of cytokines IL-6, IL-8 IL-10 and IL-12 ), and the mediating role of well-being measures on the relations between optimism and perceived control with immune measures.

Methods Participants will include 120 colorectal cancer patients aged 18+, with Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2 and disease stage II or III, who receive adjuvant chemotherapy of Capecitabine (Xeloda) or FU-5 treatment, conjoined with Oxaliplatin, or Capecitabine alone following curative surgery at Rambam Health Care Campus. The estimated number of participants was calculated based on Green's equation (1991): 50+8X 7 (The Regression Model requires 50 participants + 8 participants for each variable). Possible parameters that will be monitored using the regression analysis will be: age, gender, blood Albumin level, morbidity (including: diabetes, hypertension, heart disease, stroke, arthritis), optimism and control perception. A comparison between the two treatment groups, as well as a comparison between each treatment group and the control group (80 subjects) will allow inclusion of up to four background parameters in each of the regressions, according to Green's equation. Due to the large number of background parameters that can be potential confounding variables, only parameters with significant association to the dependent variables will be included. In the univariate statistical analysis, analysis of variance (ANOVA) will be conducted in order to compare the study groups. In addition, a comparison of outcome parameters before and after the intervention period will be conducted using paired t-tests and Repeated measure analysis. As the calculated sample size and the statistical power are sufficient for the regression analysis (multivariate statistical analysis), they are also suitable for the univariate statistical analysis.

Following recruitment, participants will be randomly divided into 2 intervention groups:

biofeedback-assisted relaxation or wheatgrass consumption. The control group will consist of subjects who were not interested in participating in the active intervention, but agreed to contribute blood samples during chemotherapy treatments for the purpose of the study. This study design was selected as expected recruitment rate will not allow for a random allocation for test and control groups. However, this control will enable us to compare immune parameters of patients who refused to participate in this study, with those who were allocated to each group, in order to neutralize the effect of the oncology treatment and to compare the groups. In addition, each treatment group can be evaluated for immune and well-being parameters, each subject's pre-treatment status serving as a control for his post-treatment status.

Blood samples will be collected at baseline (the onset of chemotherapy), and then again 3 and 6 months later for measuring the levels of cytokines (IL-6, IL-8, IL-10, IL-12) in the serum and in micro-particles. Well-being will be assessed at the same 3 time points via questionnaires, including emotional and physical symptoms: anxiety, depression, pain, nausea and vomiting, and chronic fatigue levels. Demographical and medical information will be taken from the medical records. The two study interventions will continue for 6 months (the chemotherapy treatment period). (1) Biofeedback-assisted relaxation intervention group: participants will receive biofeedback devices to practice relaxation at home. Four sessions will be conducted with a psychologist specializing in biofeedback therapy. During these sessions, relaxation techniques will be learned and practiced. (2) Wheatgrass intervention group: Each patient will be supplied with frozen wheatgrass juice divided into daily doses of 60 cc. Patients will be asked to drink one dose every morning on an empty stomach.

Study importance and potential contribution This is a first study to examine the possible effects of biofeedback-assisted relaxation vs. wheatgrass juice on immune and well-being parameters among colorectal cancer patients. To the best of our knowledge, this is the first study to investigate the possible effects of biofeedback-assisted relaxation on serum levels of the pro-inflammatory cytokines. Using a randomized controlled design with three time points and a homogenous sample in terms of disease parameters, type of treatment and functional status will allow us to obtain valid results regarding the psychological and physical parameters of well-being and pro-inflammatory biomarkers. Possible verification of the study hypotheses will add to the theoretical knowledge on the effects of personal resources and psychological well-being on immune measures and may suggest potential ways to improve well-being as well as cancer-related symptoms, and even disease course among colorectal cancer patients

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 200
• Est. completion date: December 2018
• Est. primary completion date: December 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 100 Years

Eligibility

Inclusion Criteria:

1. colon cancer patients receiving adjuvant treatment as described above after hysterectomy surgery.

2. stage II or III disease

3. age over 18 years.

4. functional status (PS) = 2 (0-2 WHO performance status)

5. patients hospital Rambam Medical Center6. signing of the informed consent form

Exclusion Criteria:

1. patients taking psychiatric drugs because of depression, anxiety or another disorder that requires psychiatric intervention.

2. comorbidity that directly affects the immune indices (such as autoimmune diseases, immune deficiency)3. difficulty in understanding the Hebrew language-these patients can be included in the control group

Related Conditions & MeSH terms

• Colon Cancer
• Colorectal Neoplasms

Intervention

Behavioral:
• biofeedback
Patients will go through biofeedback sessions

Drug:
• Wheatgerm juice
Patient will drink wheatgerm juice

Locations

Country	Name	City	State
Israel	Oncology Institute, Rambam Health Care Campus	Haifa

Sponsors (1)

Lead Sponsor	Collaborator
Rambam Health Care Campus

Country where clinical trial is conducted

Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Primary Outcome	1.The differences in the level of the inflammatory cytokines IL-6, 8-6, IL10, IL-12, in serum and microparticles.; between two methods of intervention (relaxation in combination with biofeedback or wheatgrass juice consumption) or control group of patients with colorectal cancer under chemotherapy adjuvant treatment.	six months or end of adjuvant chemotherapy
Secondary	Secondary	Quality of life according to Q30-EORTC between two methods of intervention (relaxation in combination with biofeedback or wheatgrass juice consumption) or control group of patients with colorectal cancer under chemotherapy adjuvant treatment.	six months or end of adjuvant chemotherapy treatment
Secondary	secondary	Depression according to HADS questionaire between two methods of intervention (relaxation in combination with biofeedback or wheatgrass juice consumption) or control group of patients with colorectal cancer under chemotherapy adjuvant treatment.	six months or end of adjuvant chemotherapy
Secondary	secondary	Anxiety according HADS questionaire between two methods of intervention (relaxation in combination with biofeedback or wheatgrass juice consumption) or control group of patients with colorectal cancer under chemotherapy adjuvant treatment.	Six months or end of adjuvant chemotherapy